BRPI0201437B8 - processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos - Google Patents

processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos

Info

Publication number
BRPI0201437B8
BRPI0201437B8 BRPI0201437A BRPI0201437B8 BR PI0201437 B8 BRPI0201437 B8 BR PI0201437B8 BR PI0201437 A BRPI0201437 A BR PI0201437A BR PI0201437 B8 BRPI0201437 B8 BR PI0201437B8
Authority
BR
Brazil
Prior art keywords
processes
deoxo
aza
substituted
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Sklavounos Constantine
Teresa Negri Joanna
Lloyd Tucker John
Peter Mahon Kerry Jr
Wei Lulin
Dietrich Hammen Philip
Shelton Lehner Richard
Original Assignee
Pah Usa 15 Llc
Pfizer Prod Inc
Zoetis P Llc
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pah Usa 15 Llc, Pfizer Prod Inc, Zoetis P Llc, Zoetis Services Llc filed Critical Pah Usa 15 Llc
Publication of BR0201437A publication Critical patent/BR0201437A/pt
Publication of BRPI0201437B1 publication Critical patent/BRPI0201437B1/pt
Publication of BRPI0201437B8 publication Critical patent/BRPI0201437B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos". esta invenção refere-se aos processos de preparação de compostos da fórmula 1. em que r 3 é definido como aqui, e de seus sais aceitáveis farmaceuticamente, bem como de intermediários úteis neste processo. os composto da fórmula 1 são agentes antibacterianos que podem ser utilizados para o tratamento de várias infecções bacterianas e de protozoários. a invenção também refere-se a composições farmacêuticas contendo compostos preparados pelos processos da invenção e a métodos de tratamento de infecções bacterianas e de protozoários, pela administração de tais compostos.
BR0201437-8 2001-04-27 2002-04-26 processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos BRPI0201437B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28720301P 2001-04-27 2001-04-27
US60/287,203 2001-04-27

Publications (3)

Publication Number Publication Date
BR0201437A BR0201437A (pt) 2003-06-10
BRPI0201437B1 BRPI0201437B1 (pt) 2017-11-28
BRPI0201437B8 true BRPI0201437B8 (pt) 2021-05-25

Family

ID=23101880

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209241-7A BR0209241A (pt) 2001-04-27 2002-04-11 Processo para preparação de derivados de9-deoxo-9a-aza-9a-homoeritromicina a 4-substituida
BR0201437-8 BRPI0201437B8 (pt) 2001-04-27 2002-04-26 processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0209241-7A BR0209241A (pt) 2001-04-27 2002-04-11 Processo para preparação de derivados de9-deoxo-9a-aza-9a-homoeritromicina a 4-substituida

Country Status (22)

Country Link
US (1) US6825327B2 (pt)
EP (2) EP1383780A1 (pt)
JP (3) JP4104463B2 (pt)
KR (1) KR100474225B1 (pt)
CN (4) CN1297564C (pt)
AR (1) AR035871A1 (pt)
AU (1) AU784362B2 (pt)
BR (2) BR0209241A (pt)
CA (2) CA2445306C (pt)
CZ (1) CZ303716B6 (pt)
DK (1) DK1253153T3 (pt)
ES (1) ES2608848T3 (pt)
HU (1) HU230717B1 (pt)
IL (3) IL158059A0 (pt)
MX (2) MXPA03009786A (pt)
PL (2) PL371766A1 (pt)
PT (1) PT1253153T (pt)
RU (2) RU2263117C2 (pt)
SG (1) SG100789A1 (pt)
WO (1) WO2002088158A1 (pt)
YU (1) YU29502A (pt)
ZA (2) ZA200203252B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN101039668A (zh) * 2004-08-13 2007-09-19 先灵-普劳有限公司 包含抗菌素、三唑和皮质类固醇的药物制剂
DE602005009381D1 (de) 2004-09-23 2008-10-09 Schering Plough Ltd Bekämpfung von parasiten in tieren durch verwendung neuer trifluormethansulfonanilidoximetherderivate
DE602005017419D1 (de) 2004-11-19 2009-12-10 Schering Plough Ltd Kontrolle von parasiten bei tieren mittels verwendung von parasitiziden 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitril-derivaten
EP1841437B1 (en) * 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
AR054380A1 (es) * 2005-06-09 2007-06-20 Schering Plough Ltd Control de parasitos en animales con derivados de n- ((feniloxi) fenil) -1,1,1-trifluorometansulfonamida y de n-(fenilsulfanil) fenil) -1,1,1-trifluorometansulfonamida
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
MX2009006282A (es) * 2006-12-13 2009-06-23 Schering Plough Ltd Profarmacos solubles en agua de florfenicol y sus analogos.
EP2102154A1 (en) * 2006-12-13 2009-09-23 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
EP2182945B1 (en) 2007-06-27 2015-08-05 E. I. du Pont de Nemours and Company Animal pest control method
TWI468407B (zh) 2008-02-06 2015-01-11 Du Pont 中離子農藥
JP2011529895A (ja) * 2008-07-30 2011-12-15 インターベツト・インターナシヨナル・ベー・ベー フロルフェニコール中間体として有用なオキサゾリン保護アミノジオール化合物を調製する方法
WO2010086351A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 3'-n-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity
KR20120050467A (ko) 2009-08-05 2012-05-18 이 아이 듀폰 디 네모아 앤드 캄파니 메소이온성 살충제
WO2011017347A2 (en) 2009-08-05 2011-02-10 E. I. Du Pont De Nemours And Company Mesoionic pesticides
UA110924C2 (uk) 2009-08-05 2016-03-10 Е. І. Дю Пон Де Немур Енд Компані Мезоіонні пестициди
UA107804C2 (xx) 2009-08-05 2015-02-25 Du Pont Суміші мезоіонних пестицидів
EP2576523B1 (en) 2010-05-27 2016-01-13 E. I. du Pont de Nemours and Company Crystalline form of 4-[5 - [3 -chloro-5 -(trifluoromethyl)phenyl] -4,5 -dihydro-5 -(trifluoromethyl)-3 - isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naphthalenecarboxamide
EP2588084B1 (en) * 2010-07-01 2023-11-22 Elanco Tiergesundheit AG Antibiotic compositions comprising tulathromycin
US8940880B2 (en) 2010-09-20 2015-01-27 Novartis Ag Process for the preparation of 9-deoxo-9a-homoerythromycin A, modified in the C-4″ of the cladinose ring by an epoxide group
WO2012087630A1 (en) 2010-12-20 2012-06-28 E.I. Du Pont De Nemours And Company Pyridine and pyrimidine compounds for controlling invertebrate
CN102295672B (zh) * 2011-07-13 2014-06-04 武汉回盛生物科技有限公司 一种泰拉菌素的合成方法
CN102260306B (zh) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 一种制备泰拉霉素的方法
WO2013013834A1 (en) * 2011-07-27 2013-01-31 Farma Grs, D.O.O. New crystalline forms of tulathromycin
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN103965273B (zh) 2013-08-23 2016-05-25 普莱柯生物工程股份有限公司 一种大环内酯类化合物
CN103497227B (zh) * 2013-09-13 2015-09-30 青岛科技大学 一种泰拉菌素中间体的制备方法
BR112018014534B1 (pt) * 2016-01-18 2022-08-23 Zhejiang Hisun Pharmaceutical Co., Ltd Método e intermediário para a preparação de tulatromicina
CN106046077B (zh) * 2016-08-04 2019-07-26 湖北美天生物科技股份有限公司 一种泰拉霉素a的合成方法
CN106434797A (zh) * 2016-08-25 2017-02-22 艾美科健（中国）生物医药有限公司 一种酶法合成泰拉霉素的工艺
CN106939029B (zh) * 2017-04-28 2020-10-13 艾美科健（中国）生物医药有限公司 一种泰拉霉素的制备方法
CN107556351B (zh) * 2017-08-29 2019-10-18 博瑞生物医药（苏州）股份有限公司 一种泰拉菌素的制备方法
CN107400152B (zh) * 2017-08-29 2019-10-15 博瑞生物医药（苏州）股份有限公司 泰拉菌素草酸盐
CN109535210A (zh) * 2018-12-19 2019-03-29 江苏威凌生化科技有限公司 一种合成纯化泰拉霉素杂质e的方法
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
CN111072730B (zh) * 2019-12-16 2021-01-12 浙江国邦药业有限公司 一种泰拉霉素中间体盐的制备方法及应用
CN112225769A (zh) * 2020-09-21 2021-01-15 江苏威凌生化科技有限公司 一种合成纯化泰拉霉素杂质e的方法
CN113493483A (zh) * 2021-07-05 2021-10-12 上海应用技术大学 一种泰拉霉素的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI7910768A8 (en) 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4512982A (en) 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4518590A (en) 1984-04-13 1985-05-21 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method
CA2064634C (en) 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
EP0549040A1 (en) 1991-12-20 1993-06-30 Merck & Co. Inc. Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
HN1998000074A (es) * 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
HUP0201341A3 (en) * 1999-05-18 2003-03-28 Pfizer Prod Inc Novel crystalline forms of a macrolide antibiotic, process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
JP4104463B2 (ja) 2008-06-18
ZA200203252B (en) 2003-10-24
EP1253153A1 (en) 2002-10-30
IL149226A0 (en) 2002-11-10
WO2002088158A1 (en) 2002-11-07
BRPI0201437B1 (pt) 2017-11-28
AU784362B2 (en) 2006-03-16
ZA200307506B (en) 2005-01-26
CA2383409A1 (en) 2002-10-27
IL158059A0 (en) 2004-03-28
CN1384108A (zh) 2002-12-11
HUP0201385A2 (hu) 2003-12-29
CN1295240C (zh) 2007-01-17
CN1297564C (zh) 2007-01-31
CN1503804A (zh) 2004-06-09
SG100789A1 (en) 2003-12-26
BR0209241A (pt) 2004-06-15
MXPA03009786A (es) 2004-01-29
RU2003131351A (ru) 2005-02-27
CN1530370A (zh) 2004-09-22
MXPA02004231A (es) 2002-11-13
JP2002326998A (ja) 2002-11-15
CA2445306C (en) 2008-02-12
CN1715289A (zh) 2006-01-04
EP1383780A1 (en) 2004-01-28
RU2233287C2 (ru) 2004-07-27
PT1253153T (pt) 2016-12-29
AU3563002A (en) 2002-10-31
YU29502A (sh) 2005-03-15
CZ20021417A3 (cs) 2003-05-14
HK1065803A1 (en) 2005-03-04
CZ303716B6 (cs) 2013-04-03
JP4100955B2 (ja) 2008-06-11
JP2004528353A (ja) 2004-09-16
RU2263117C2 (ru) 2005-10-27
CN1167708C (zh) 2004-09-22
BR0201437A (pt) 2003-06-10
JP2007091754A (ja) 2007-04-12
IL182418A0 (en) 2008-01-06
KR20020083474A (ko) 2002-11-02
CA2445306A1 (en) 2002-11-07
KR100474225B1 (ko) 2005-03-08
US6825327B2 (en) 2004-11-30
IL182418A (en) 2012-07-31
ES2608848T3 (es) 2017-04-17
EP1253153B1 (en) 2016-11-02
CN100413879C (zh) 2008-08-27
PL213731B1 (pl) 2013-04-30
CA2383409C (en) 2007-01-02
HK1050370A1 (en) 2003-06-20
HU230717B1 (hu) 2017-11-28
PL371766A1 (en) 2005-06-27
US20030064939A1 (en) 2003-04-03
HU0201385D0 (pt) 2002-06-29
IL149226A (en) 2008-06-05
DK1253153T3 (da) 2017-01-02
AR035871A1 (es) 2004-07-21
PL353633A1 (en) 2002-11-04

Similar Documents

Publication Publication Date Title
BRPI0201437B8 (pt) processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI9810519A (pt) derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BR0114321A (pt) Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
BRPI0415437A (pt) composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
BRPI0414330A (pt) composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR9814601A (pt) "macrólidos"
MXPA03005464A (es) Agentes antivirales.
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR9810021A (pt) Derivados 9-oxima-eritromicina
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BR9916969A (pt) Antibióticos cetólidos
BR0010938A (pt) Derivados da 13-metil eritromicina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: PAH USA 15 LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: ZOETIS P LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/04/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2720 DE 23-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.